Skip to content ↓

Resources

Featured

Join SHYFT at PMSA 2019

The SHYFT team will be at the PMSA Annual Conference in San Diego April 14th to the 17th, 2019. Stop by our booth and see…

Join SHYFT at the Rare Disease Market Access and Commercialization Summit

The SHYFT team will be at the Rare Disease Market Access and Commercialization Summit in Philadelphia March 11th and 12th, 2019 . Stop by our…

Join SHYFT at the SCOPE 2019 Summit

The expert SHYFT RWE team will be alongside Medidata at the Summit for Clinical Ops Executives (SCOPE) in Orlando February 18th to the 21st, 2019.

Categories:
All
Articles
Events
Industry Insights
News
Webinars
White Papers

Recent Posts

SHYFT’s roundup of life sciences and data analytics news-12/18/15 edition
Industry Insights

SHYFT’s roundup of life sciences and data analytics news-12/18/15 edition

Medidata Defines the Future of Life Sciences with Acquisition of SHYFT Analytics   Leading the digital transformation of life sciences with artificial intelligence and advanced analytics NEW YORK — June 12, 2018 — Medidata (NASDAQ: MDSO) today announced that it has entered into a definitive agreement to acquire…

Join SHYFT at the Trade and Channel Strategies Conference
Events

Join SHYFT at the Trade and Channel Strategies Conference

The SHYFT team will be at CBI’s Trade and Channel Strategies conference in Philadelphia December 11th and 12th, 2018 . Stop by our booth and see a demo of our leading data management and analytics solutions.

PAREXEL and SHYFT Analytics Partner to Deliver Faster, More Dynamic Real-World Data Studies
Articles

PAREXEL and SHYFT Analytics Partner to Deliver Faster, More Dynamic Real-World Data Studies

PAREXEL and SHYFT Analytics Partner to Deliver Faster, More Dynamic Real-World Data Studies  SHYFT’s leading platform to become PAREXEL’s foundation for outcomes analysis in support of clinical development and commercialization Waltham, Mass. – November 8, 2018 – SHYFT Analytics, a Medidata Solutions (NASDAQ:MDSO) company, and PAREXEL International,…

SHYFT to Develop a Launch Plan for Tetraphase Pharmaceuticals
News

SHYFT to Develop a Launch Plan for Tetraphase Pharmaceuticals

Priya Sapra, SHYFT’s SVP, Product & Customer Engagement, talks to Pharmaceutical Commerce about SHYFT’s recent selection by Tetraphase Pharmaceuticals to support data and analytics for commercial launch readiness. SHYFT’s Platform will support the anticipated commercial launch of eravacycline, Tetraphase’s  lead antibiotic candidate developed to address multidrug-resistant bacteria.